WATERTOWN, Mass.--(BUSINESS WIRE)--Panacos Pharmaceuticals, Inc. (Nasdaq:PANC), a biotechnology company dedicated to developing the next generation of antiviral therapeutic products, today announced that it has initiated a Phase 1 clinical trial of PA-1050040 (also referred to as "PA-040"), an investigational maturation inhibitor for the treatment of HIV.
